These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 21383727)

  • 21. Regulations, economics hindering adoption of personalized medicine.
    Thompson CA
    Am J Health Syst Pharm; 2011 Mar; 68(5):372-4. PubMed ID: 21330674
    [No Abstract]   [Full Text] [Related]  

  • 22. Pharmacists as investigators in FDA-regulated drug trials.
    Okubanjo T; Gonzalez LS
    Am J Health Syst Pharm; 2008 Jun; 65(11):1010-1. PubMed ID: 18499871
    [No Abstract]   [Full Text] [Related]  

  • 23. FDA designations for therapeutics and their impact on drug development and regulatory review outcomes.
    Kesselheim AS; Darrow JJ
    Clin Pharmacol Ther; 2015 Jan; 97(1):29-36. PubMed ID: 25670381
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Flexibility and innovation in the FDA's novel regulatory approval strategies for hematologic drugs.
    Farrell AT; Goldberg KB; Pazdur R
    Blood; 2017 Sep; 130(11):1285-1289. PubMed ID: 28774876
    [No Abstract]   [Full Text] [Related]  

  • 25. How pharmacogenomics will impact the federal regulation of clinical trials and the new drug approval process.
    Binzak BA
    Food Drug Law J; 2003; 58(1):103-27. PubMed ID: 12739592
    [No Abstract]   [Full Text] [Related]  

  • 26. International Conference on Harmonisation; guidance on ethnic factors in the acceptability of foreign clinical data; availability--FDA. Notice.
    Fed Regist; 1998 Jun; 63(111):31790-6. PubMed ID: 10180134
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Food and drug administration approval process for dermatology drugs in the United States.
    Boozalis E; Semenov YR; Kwatra SG
    J Dermatolog Treat; 2018 Sep; 29(6):536-538. PubMed ID: 29304565
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The United States Food and Drug Administration and the end of antibiotics.
    Shlaes DM; Moellering RC
    Clin Infect Dis; 2002 Feb; 34(3):420-2. PubMed ID: 11774094
    [No Abstract]   [Full Text] [Related]  

  • 29. More Than One Way to Measure? A Casuistic Approach to Cancer Clinical Trials.
    Andreoletti M
    Perspect Biol Med; 2018; 61(2):174-190. PubMed ID: 30146517
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug development in inflammatory bowel disease: the role of the FDA.
    Lahiff C; Kane S; Moss AC
    Inflamm Bowel Dis; 2011 Dec; 17(12):2585-93. PubMed ID: 21484967
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FDA Advisory Committee stalemates on delavirdine.
    AIDS Patient Care STDS; 1997 Apr; 11(2):96-7. PubMed ID: 11361773
    [No Abstract]   [Full Text] [Related]  

  • 32. Will FDA relinquish the "gold standard" for new drug approval? Redefining "substantial evidence" in the FDA Modernization Act of 1997.
    Kulynych J
    Food Drug Law J; 1999; 54(1):127-49. PubMed ID: 11758555
    [No Abstract]   [Full Text] [Related]  

  • 33. The FDA Breakthrough-Drug Designation - Four Years of Experience.
    Darrow JJ; Avorn J; Kesselheim AS
    N Engl J Med; 2018 Apr; 378(15):1444-1453. PubMed ID: 29641970
    [No Abstract]   [Full Text] [Related]  

  • 34. Preparing for an FDA audit.
    Barnes D
    Epilepsy Res Suppl; 1993; 10():245-50. PubMed ID: 8251103
    [No Abstract]   [Full Text] [Related]  

  • 35. Clinical trials performed for the new drug approval process in the United States: standard methods and alternative methods.
    Browne TR
    Epilepsy Res Suppl; 1993; 10():31-44. PubMed ID: 8251105
    [No Abstract]   [Full Text] [Related]  

  • 36. Teaching the elephant to dance: privatizing the FDA review process.
    Price EC
    Food Drug Law J; 1996; 51(4):651-76. PubMed ID: 11797734
    [No Abstract]   [Full Text] [Related]  

  • 37. Accelerated approval of oncology products: the food and drug administration experience.
    Johnson JR; Ning YM; Farrell A; Justice R; Keegan P; Pazdur R
    J Natl Cancer Inst; 2011 Apr; 103(8):636-44. PubMed ID: 21422403
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulatory watch: FDA new drug approvals in Q2 2018.
    Urquhart L
    Nat Rev Drug Discov; 2018 Jul; 17(8):536-537. PubMed ID: 30057412
    [No Abstract]   [Full Text] [Related]  

  • 39. Progress and deficiencies in the registration of clinical trials.
    Wood AJ
    N Engl J Med; 2009 Feb; 360(8):824-30. PubMed ID: 19228628
    [No Abstract]   [Full Text] [Related]  

  • 40. Changes at FDA may speed drug approval process and increase off-label use.
    Reh M
    J Natl Cancer Inst; 1998 Jun; 90(11):805-7. PubMed ID: 9625166
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.